+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-11-02Number of Pages: 150

Glaucoma Therapeutics Market (Drug Class - Prostaglandins, Beta Blockers, Combined Medication, Alpha Agonist, Carbonic Anhydrase Inhibitors, and Cholinergic; End User - Hospitals, Ophthalmic Clinics, and Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Glaucoma Therapeutics Market: Snapshot

The American Association of Ophthalmology states that an estimated three million people in the U.S. have glaucoma. The organization has found that glaucoma is a leading cause of blindness for people over the age of 60. However, blindness resulting from glaucoma can often be prevented with early medical intervention – be it diagnosis or treatment.

A significant rise in the awareness of glaucoma, a growing demand for combination glaucoma drugs, and the availability of medical insurance coverage for diagnosis and treatment are some of the prominent trends observed in the global glaucoma therapeutics market. The market is also fueled by the increasing geriatric population in developed nations, a surge in healthcare expenditure, and the development of advanced drug delivery devices. Riding on these factors, the global glaucoma therapeutics market is projected to rise from a value of US$5.7 bn in 2015 to US$7.6 bn by 2024 at a modest CAGR of 3.4% therein.

On the other hand, the side effects of glaucoma medications, stringent government regulations pertaining to approvals and marketing, and a lengthy process for the development of glaucoma products threatens to hamper the growth of the market.

glaucoma therapeutics market

 

Hospitals Most Preferred End-use Segment

The global glaucoma therapeutics market is segmented according to the class of drug into prostaglandins, beta blockers, alpha agonist, combines medication, carbonic anhydrase inhibitors, and cholinergic.

Among these, prostaglandins, beta blockers, and combined medication are the most widely used topical agents. Over the forecast period, it is estimated that combined medication will acquire the majority of the market, followed by beta blockers and prostaglandins. However, the increasing prevalence of glaucoma globally has resulted in the strong growth of the combined medication segment and it is expected to record a high CAGR during the forecast period. Growing awareness about the early detection of glaucoma and the availability of affordable treatment options are expected to boost the glaucoma therapeutics market in the coming years.

By end use, the hospitals segment captured a major share in the market and is likely to sustain its leadership position throughout the forecast period. A large section of the population prefers visiting hospitals rather than ophthalmic clinics for treatment as the cost of therapy at hospitals is relatively lower. Ambulatory surgical centers, on the other hand, are presently playing a rather minor role in the development of the global glaucoma therapeutics market.

North America and Europe Accounted for 3/4 of Global Market in 2015

On the basis of geography, the global market for glaucoma therapeutics has been divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe accounted for a combined share of just short of 75.0% in 2015.

North America is expected to continue its dominance in the market during the forecast period due to an increase in geriatric population, growing awareness regarding glaucoma and the availability of various treatment options, the existence of a favorable reimbursement scenario, and a well-established healthcare infrastructure.

Europe is also a major player in the glaucoma therapeutics market and is expected to retain its significant position in the global market through 2024 due to a surge in the volume sales of topical eye drops, especially beta blockers, and the upcoming launch of combined medication products.

Asia Pacific is a rather attractive market and is expected to expand at a rapid CAGR from 2016 to 2024. The market in Latin America and the Middle East and Africa, on the other hand, are expected to witness sluggish growth over the course of the forecast period. However, the increased focus of the federal governments on enhancing healthcare facilities and rising awareness among the population will give the regions a much-needed boost.

Major players operating in the glaucoma therapeutics market include Allergan Inc., Merck & Co., Pfizer Inc., Novartis AG., Santen Pharmaceuticals, Valeant Pharmaceuticals, and Aerie Pharmaceuticals. Players offering generic therapeutics include Fera Pharmaceuticals, Teva Pharmaceuticals, and Aristo Pharmaceuticals.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Glaucoma Therapeutics Market 

4. Market Overview
     4.1. Introduction
            4.1.1. Class of Drug Definition
            4.1.2. Industry Evolution / Developments
     4.2.  Overview
     4.3. Key Market Indicators
            4.3.1. Region/Country Specific
            4.3.2. Target Market Specific – Global Scenario
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
            4.4.4. Trends 
     4.5. Global Glaucoma Therapeutics Market  Analysis and Forecasts, 2014–2024
            4.5.1. Market Volume Projections, 2014–2024
            4.5.2. Pricing  - Actuals and Projections, 2014–2024
            4.5.3. Market Revenue Projections (US$ Mn)
     4.6. Global Glaucoma Therapeutics Market  - Global Supply Demand Scenario
     4.7. Porter’s Five Force Analysis
     4.8. Value Chain Analysis
     4.9. Market Outlook

5. Global Glaucoma Therapeutics Market  Analysis and Forecasts, By Class of Drug 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends
     5.4. Market Value  Forecast By Class of Drug , 2014–2024
            5.4.1. Prostaglandins
            5.4.2. Alpha Agonist 
            5.4.3. Beta Blockers
            5.4.4. Carbonic Anhydrase Inhibitor 
            5.4.5. Cholinergic 
            5.4.6. Combined Medication
     5.5. Class of Drug  Comparison Matrix
     5.6. Market Attractiveness By Class of Drug 

6. Global Glaucoma Therapeutics Market  Analysis and Forecasts, By End Users 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market Value  Forecast By End Users , 2014–2024
            6.4.1. Ophthalmic Clinic
            6.4.2. Hospitals 
            6.4.3. Ambulatory Surgical Centers 
     6.5. End Users  Comparison Matrix
     6.6. Market Attractiveness By End Users 

7. Global Glaucoma Therapeutics Market  Analysis and Forecasts, By Region
     7.1. Key Findings
     7.2. Policies and Regulations
     7.3. Market Value  Forecast By Region
            7.3.1. North America 
            7.3.2. Europe 
            7.3.3. Asia Pacific 
            7.3.4. Latin America  
            7.3.5. Middle East & Africa 
     7.4. Market Attractiveness By Country/Region

8. North America Global Glaucoma Therapeutics Market  Analysis and Forecast
     8.1. Introduction
            8.1.1. Key Findings
            8.1.2. Policies and Regulations
            8.1.3. Price Trend Analysis
            8.1.4. Key Trends
     8.2. Market Value  Forecast By Class of Drug , 2014–2024
            8.2.1. Prostaglandins
            8.2.2. Alpha Agonist 
            8.2.3. Beta Blockers
            8.2.4. Carbonic Anhydrase Inhibitor 
            8.2.5. Cholinergic 
            8.2.6. Combined Medication
     8.3. Market Value  Forecast By End Users , 2014–2024
            8.3.1. Ophthalmic Clinic
            8.3.2. Hospitals 
            8.3.3. Ambulatory Surgical Centers 
     8.4. Market Value  Forecast By Country , 2014–2024
            8.4.1. U.S.
            8.4.2. Canada
     8.5. Market Attractiveness Analysis 
            8.5.1. By Class of Drug 
            8.5.2. By End Users 
            8.5.3. By Country

9. Europe Global Glaucoma Therapeutics Market  Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
            9.1.2. Policies and Regulations
            9.1.3. Price Trend Analysis
            9.1.4. Key Trends
     9.2. Market Value  Forecast By Class of Drug , 2014–2024
            9.2.1. Prostaglandins
            9.2.2. Alpha Agonist 
            9.2.3. Beta Blockers
            9.2.4. Carbonic Anhydrase Inhibitor 
            9.2.5. Cholinergic 
            9.2.6. Combined Medication
     9.3. Market Value  Forecast By End Users , 2014–2024
            9.3.1. Ophthalmic Clinic
            9.3.2. Hospitals 
            9.3.3. Ambulatory Surgical Centers 
     9.4. Market Value  Forecast By Country , 2014–2024
            9.4.1. Germany
            9.4.2. U.K.
            9.4.3. France
            9.4.4. Spain
            9.4.5. Italy
            9.4.6. Rest of Europe 
     9.5. Market Attractiveness Analysis 
            9.5.1. By Class of Drug 
            9.5.2. By End Users 
            9.5.3. By Country

10. Asia Pacific Global Glaucoma Therapeutics Market  Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
            10.1.2. Policies and Regulations
            10.1.3. Price Trend Analysis
            10.1.4. Key Trends
     10.2. Market Value  Forecast By Class of Drug , 2014–2024
            10.2.1. Prostaglandins
            10.2.2. Alpha Agonist 
            10.2.3. Beta Blockers
            10.2.4. Carbonic Anhydrase Inhibitor 
            10.2.5. Cholinergic 
            10.2.6. Combined Medication
     10.3. Market Value  Forecast By End Users , 2014–2024
            10.3.1. Ophthalmic Clinic
            10.3.2. Hospitals 
            10.3.3. Ambulatory Surgical Centers 
     10.4. Market Value  Forecast By Country , 2014–2024
            10.4.1. Japan
            10.4.2. China
            10.4.3. Australia
            10.4.4. New Zealand
            10.4.5. India
            10.4.6. Rest of Asia Pacific
     10.5. Market Attractiveness Analysis 
            10.5.1. By Class of Drug 
            10.5.2. By End Users 
            10.5.3. By Country

11. Latin America  Global Glaucoma Therapeutics Market  Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
            11.1.2. Policies and Regulations
            11.1.3. Price Trend Analysis
            11.1.4. Key Trends
     11.2. Market Value  Forecast By Class of Drug , 2014–2024
            11.2.1. Prostaglandins
            11.2.2. Alpha Agonist 
            11.2.3. Beta Blockers
            11.2.4. Carbonic Anhydrase Inhibitor 
            11.2.5. Cholinergic 
            11.2.6. Combined Medication
     11.3. Market Value  Forecast By End Users , 2014–2024
            11.3.1. Ophthalmic Clinic
            11.3.2. Hospitals 
            11.3.3. Ambulatory Surgical Centers 
     11.4. Market Value  Forecast By Country , 2014–2024
            11.4.1. Brazil
            11.4.2. Mexico
     11.5. Market Attractiveness Analysis 
            11.5.1. By Class of Drug 
            11.5.2. By End Users 
            11.5.3. By Country

12. Middle East & Africa Global Glaucoma Therapeutics Market  Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
            12.1.2. Policies and Regulations
            12.1.3. Price Trend Analysis
            12.1.4. Key Trends
     12.2. Market Value  Forecast By Class of Drug , 2014–2024
            12.2.1. Prostaglandins
            12.2.2. Alpha Agonist 
            12.2.3. Beta Blockers
            12.2.4. Carbonic Anhydrase Inhibitor 
            12.2.5. Cholinergic 
            12.2.6. Combined Medication
     12.3. Market Value  Forecast By End Users , 2014–2024
            12.3.1. Ophthalmic Clinic
            12.3.2. Hospitals 
            12.3.3. Ambulatory Surgical Centers 
     12.4. Market Value  Forecast By Country , 2014–2024
            12.4.1. South Africa
            12.4.2. UAE
            12.4.3. Saudi Arabia
     12.5. Market Attractiveness Analysis 
            12.5.1. By Class of Drug 
            12.5.2. By End Users 
            12.5.3. By Country

13. Competition Landscape
     13.1. Market Player – Competition Matrix (By Tier and Size of companies)
     13.2. Market Share Analysis By Company (2015)
     13.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            13.3.1. Allergan Inc.
                      13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.1.2. Financial Overview
                      13.3.1.3. Product Portfolio
                      13.3.1.4. SWOT Analysis
                      13.3.1.5. Strategic Overview
            13.3.2. Merck & Co.
                      13.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.2.2. Financial Overview
                      13.3.2.3. Product Portfolio
                      13.3.2.4. SWOT Analysis 
                      13.3.2.5. Strategic Overview
            13.3.3. Novartis AG
                      13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.3.2. Financial Overview
                      13.3.3.3. Product Portfolio
                      13.3.3.4. SWOT Analysis 
                      13.3.3.5. Strategic Overview
            13.3.4. Pfizer Inc. 
                      13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.4.2. Financial Overview
                      13.3.4.3. Product Portfolio
                      13.3.4.4. SWOT Analysis 
                      13.3.4.5. Strategic Overview
            13.3.5. Santen Pharmaceuticals
                      13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.5.2. Financial Overview
                      13.3.5.3. Product Portfolio
                      13.3.5.4. SWOT Analysis 
                      13.3.5.5. Strategic Overview
            13.3.6. Valeant Pharmaceuticals Inc.
                      13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.6.2. Financial Overview
                      13.3.6.3. Product Portfolio
                      13.3.6.4. SWOT Analysis 
                      13.3.6.5. Strategic Overview 
            13.3.7. Aerie Pharmaceuticals Inc.
                      13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                      13.3.7.2. Financial Overview
                      13.3.7.3. Product Portfolio
                      13.3.7.4. SWOT Analysis 
                      13.3.7.5. Strategic Overview

List of Figures

Figure 1: Market Value Share, by Drug Class (2016) Revenue (US$ Mn)
Figure 2: Market Value Share, by End-user (2016) Revenue (US$ Mn)
Figure 3: Market Value Share, by Region (2016) Revenue (US$ Mn)
Figure 4: Global Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 5: Global Prostaglandins Market Revenue (US$ Mn), 2014–2024
Figure 6: Global Beta Blockers Market Revenue (US$ Mn), 2014–2024
Figure 7: Global Alpha Agonist Market, Revenue (US$ Mn), 2014–2024
Figure 8: Global Carbonic Anhydrase Inhibitor Market, Revenue (US$ Mn), 2014–2024
Figure 9: Global Combined Medication Market, Revenue (US$ Mn), 2014–2024
Figure 10: Global Cholinergic Market, Revenue (US$ Mn), 2014–2024
Figure 11: Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 12: Global Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2015 and 2024
Figure 13: Global Hospital Market Revenue (US$ Mn), 2014–2024
Figure 14: Global Ophthalmic Clinics Market Revenue (US$ Mn), 2014–2024
Figure 15: Global Ambulatory Surgical Centers Market Revenue (US$ Mn), 2014–2024
Figure 16: Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2015
Figure 17: Global Glaucoma Therapeutics Market Value Share Analysis, by Region, 2015 and 2024
Figure 18: Glaucoma Therapeutics Market Attractiveness Analysis, by Region, 2015
Figure 19: North America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 20: North America Glaucoma Therapeutics Market Attractiveness Analysis, by Country, 2015
Figure 21: North America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 22: North America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2015 and 2024
Figure 23: North America Glaucoma Therapeutics Market by Country, 2015 and 2024
Figure 24: North America Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 25: North America Glaucoma Therapeutics Market Attractiveness Analysis, by End User, 2015
Figure 26: Europe Glaucoma Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure 27: Europe Glaucoma Therapeutics Market Attractiveness Analysis, by Country, 2015
Figure 28: Europe Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 29: Europe Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2015 and 2024
Figure 30: Europe Glaucoma Therapeutics Market by Country, 2015 and 2024
Figure 31: Europe Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 32: Europe Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2015
Figure 33: Asia Pacific Glaucoma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 34: Asia Pacific Glaucoma Therapeutics Market Attractiveness Analysis, by Country, 2015
Figure 35: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 36: Asia Pacific Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2015 and 2024
Figure 37: Asia Pacific Glaucoma Therapeutics Market by Country, 2015 and 2024
Figure 38: Asia Pacific Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 39: Asia Pacific Glaucoma Therapeutics Market Attractiveness Analysis, by End User, 2015
Figure 40: Latin America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 41: Latin America Glaucoma Therapeutics Market Attractiveness Analysis, by Country, 2015
Figure 42: Latin America Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 43: Latin America Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2015 and 2024
Figure 44: North America Glaucoma Therapeutics Market by Country, 2015 and 2024
Figure 45: Latin America Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 46: Latin America Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2015
Figure 47: Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure 48: Middle East & Africa Glaucoma Therapeutics Market Attractiveness Analysis, by Country, 2015
Figure 49: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by Drug Class, 2015 and 2024
Figure 50: Middle East & Africa Glaucoma Therapeutics Market Value Share Analysis, by End-user, 2015 and 2024
Figure 51: Middle East & Africa Glaucoma Therapeutics Market by Country, 2015 and 2024
Figure 52: Middle East & Africa Glaucoma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 53: Middle East & Africa Glaucoma Therapeutics Market Attractiveness Analysis, by End-user, 2015
Figure 54: Global Glaucoma Therapeutics Market Share Analysis, by Company (2015)

List of Tables

Table 1 Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 2 Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 3 Global Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 4 North America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 5 North America Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 6 North America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 7 Europe Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 8 Europe Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 9 Europe Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 10 Asia Pacific Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 11 Asia Pacific Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 12 Asia Pacific Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 14 Latin America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 15 Latin America Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 16 Latin America Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 17 Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 18 Middle East & Africa Glaucoma Therapeutics Market Forecast, by End-user, 2014–2024
Table 19 Middle East & Africa Glaucoma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024

Glaucoma Therapeutics Market: Overview 

Glaucoma is an ocular disease which affects the optic nerve of the iris and progression of the same results into vision loss and blindness. The treatment for glaucoma starts with topical eye drops belonging to the class of prostaglandins, beta blockers, alpha agonist, combined medication, carbonic anhydrase inhibitor and cholinergic. Administration of these eye drops reduces the production of the fluid inside eyes thereby reducing the intraocular pressure. Using topical eye drops is an alternative for surgery or delays the surgical procedure. This report analyzes the current and future prospects of the glaucoma therapeutics market based on type of drug class, end user and geography.

Glaucoma Therapeutics Market: Scope and Methodology

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major glaucoma therapeutics market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for each by drug class, end user, and geography for the period 2014 to 2024, considering the macro and micro environmental factors. The revenue generated from each product was calculated by considering number of products used in the procedures and their market demand as per their use, number of product launched, average cost of products of each sub segment, trends in industry, end user trend, and adoption rate across all the geographies. The revenue generated for drug class was calculated on the basis of prevalence of diseases, and number of people affected by the disease

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on drug class, end-user, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the glaucoma therapeutics market in the current and future scenario.

Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The study also covers detailed country analysis contributing majorly in the glaucoma therapeutics market.

Glaucoma Therapeutics Market: Competitive Landscape

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the glaucoma therapeutics market are Allergan Inc., Merck & Co., Pfizer Inc., Novartis AG., Santen Pharmaceuticals, Valeant Pharmaceuticals and Aerie Pharmaceuticals.

The glaucoma therapeutics market has been segmented as follows:

Glaucoma Therapeutics Market, by Drug Class

  • Alpha Agonist
  • Beta Blockers
  • Prostaglandin Analogs
  • Carbonic Anhydrase Inhibitor
  • Cholinergic
  • Combined Medication

Glaucoma Therapeutics Market, by End Users

  • Ophthalmic clinic
  • Hospitals
  • Ambulatory Surgical Centers

Glaucoma Therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • U.K.
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • China
    • Australia
    • New Zealand
    • Rest of Asia Pacific
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • A.E.
    • Rest of MEA


 
 
Back To Top